The Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer
Author Information
Author(s): Wan Benson, Lecavalier-Barsoum Magali
Primary Institution: McGill University
Hypothesis
Can stereotactic body radiotherapy (SBRT) improve outcomes in patients with oligometastatic non-small cell lung cancer (OM-NSCLC)?
Conclusion
Stereotactic body radiotherapy (SBRT) appears to improve outcomes in patients with oligometastatic non-small cell lung cancer when combined with standard-of-care therapies.
Supporting Evidence
- SBRT has been shown to prolong time to next-line systemic therapy.
- SBRT reduces financial burden and improves quality-adjusted life years.
- Careful patient selection is necessary to maximize benefits of SBRT.
Takeaway
This study looks at how a special type of radiation therapy can help people with a certain kind of lung cancer that has spread to a few places in the body. It seems to make them feel better and live longer.
Methodology
The article reviews published phase II and III trials and ongoing studies on the use of SBRT in OM-NSCLC.
Potential Biases
Potential bias due to non-systematic selection of studies and reliance on existing literature.
Limitations
The study is not a systematic review and relies on selected studies, which may introduce bias.
Participant Demographics
Patients with oligometastatic non-small cell lung cancer, including those with various treatment backgrounds.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website